• ES - español
  • EN - English
Parliamentary question - P-000102/2021(ASW)Parliamentary question
P-000102/2021(ASW)

Answer given by Ms Kyriakides on behalf of the European Commission

1. Via its EU Strategy for COVID-19 vaccines[1], the Commission has secured access for such vaccines for Member States as soon as they become available. T he roll out of the three vaccines having so far been authorised for the EU market — from BioNTech/Pfizer, Moderna and AstraZeneca — is ongoing in countries, focusing on priority groups, since the deliveries of vaccines, as expected, have been scarce in the beginning. More vaccines are on their way.

O n 8 January 2021, the Commission secured 300 million additional doses of the BioNTech/Pfizer vaccine, in addition to the 300 million doses first secured[2]. In addition, the Commission secured another 300 million doses from Moderna[3]. This increases the total number of vaccine doses secured to 2.6 billion[4], more than sufficient for a vaccination cycle of two doses for the entire EU population. No lack of vaccine doses is therefore foreseen. In general, Member States need to ramp up vaccination, ensuring that all available doses are used up.

2. On 17 February 2021, the Commission launched the HERA Incubator to anticipate the threat of coronavirus variants. The Incubator will focus on several key actions, including the ramping up of vaccine production[5].

3. As indicated above, the Commission, on 8 January 2021, secured 300 million additional doses of the BioNTech/Pfizer vaccine, in addition to the 300 million doses first secured. The Commission has secured vaccine doses in several rounds, according to an ever-changing situation.

Last updated: 11 March 2021
Legal notice - Privacy policy